OneMedNet Corporation
ONMD · Price history
Price at last available close
$4.46
−$1.87 (-29.54%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About OneMedNet Corporation
Primary reporting period: 2025-12-31 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
OneMedNet Corporation offers advanced solutions for clinical imaging. Their core product, iRWD, is an artificial intelligence-driven platform that securely anonymizes, searches for, and organizes imaging data. This system is utilized by their extensive network of medical and academic research institutions, with the goal of fostering significant progress in medical research, new discoveries, and diagnostic techniques across the broader field of life sciences.
How they make money
OneMedNet generates revenue by providing curated, regulatory-grade imaging Real World Data (iRWD) to life sciences companies and healthcare regulators. The company aggregates de-identified clinical images and patient records from a federated network of healthcare providers, leveraging AI/ML indexing and clinical expert curation to support regulatory compliance and research, while transitioning toward a scalable, subscription-based business model.
Products & services
The company offers iRWD (imaging Real World Data) solutions, which involve the extraction, curation, and delivery of de-identified medical imaging data and associated clinical records for use in clinical trials, regulatory submissions, and medical research.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer concentration
The company has historically disclosed risks related to customer concentration, noting that a significant portion of its revenue may be derived from a limited number of customers, as detailed in the 2025 10-K.
Suppliers, materials & equipment
No supplier relationships were confirmed in the sources reviewed. This does not mean the company has no suppliers.
Business relationships & partnerships
- Palantir Technologies — A commercial collaboration where OneMedNet utilizes the Palantir Foundry platform to power its AI-driven iRWD solutions and enable conversational search capabilities on medical data.Source
Strengths
Financial risk observations and what to check
These are saved observations about business performance, not predictions. Review the company filings alongside the interpretation below. Latest stored financial period end: 2026-06-30.
Quarterly EPS turned negative at -0.37 versus 0.78 a year earlier.
Separate recurring operating losses from noncash or one-time charges, and check cash flow rather than interpreting negative EPS as a cash-outflow amount.
Quarterly net income turned from a profit to a loss versus the same quarter last year.
Identify the causes in the interim report and distinguish operating cash use from accounting charges. Prior profitability is not a guarantee of recovery.
Diluted weighted-average shares increased 51.1% year over year.
Compare per-share results with total earnings and inspect the equity footnote. A change in weighted-average shares does not by itself establish the cause, the number of shares issued today, or the economic effect of a split.
Total debt increased 75.2% versus the same quarter last year.
Compare the added borrowing with available cash, cash generation and maturities. A percentage increase from a small starting balance can look large without measuring the full debt burden.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
26
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
38
Poor
Financial Strength
40
Business Quality / Moat
33
Management
67
Growth Quality
31
Risk / Durability
0
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
27
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
31/100
Building Historical Record
Model Score 31/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Insider activity signal is favorable
- •Elevated debt risk
- •Reverse-split headline · Sep 25, 2026
- •M&A headline · Aug 10, 2026
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
Company-specific research
Questions worth answering for ONMD
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can ONMD maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can ONMD fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Does ONMD's balance between cash and debt leave enough flexibility if business conditions weaken?
- •What specifically needs to improve for ONMD to reach sustainable profitability?
- •What future growth or profitability would be needed to justify ONMD's current valuation?
Essential Investment Snapshot
Wall Street Score
26
Opportunity Score
27
Market Cap
$26.0M
P/E Ratio
-2.4
EPS
$-1.66
52-Week High
$34.40
52-Week Low
$3.92
Beta
1.14
Shares Outstanding
4.5M
Total Revenue
$1.5M
Total Debt
$701K
Dividend
No current dividend
Liquidation Value / Share
$-0.79
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
High movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for ONMD
Detected from reported data — verify before acting.Elevated debt risk
Negative shareholder equity • Interest coverage is below 2x • Free cash flow is negative
Reverse-split headline · Sep 25, 2026
OneMedNet Corporation Announces 1-for-10 Reverse Stock Split — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
GlobeNewsWireM&A headline · Aug 10, 2026
OneMedNet (NASDAQ:ONMD) Director Acquires $999,999.75 in Stock — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
Defense WorldCommunity Sentiment
0 active · 0 total callsNo personal call yet on ONMD.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary AI/ML indexing and clinical expert curation for regulatory-grade data.
- +Federated network of healthcare providers for data aggregation.
Potential downside factors
- −Debt risk (elevated): Negative shareholder equity.
- −Interest coverage is below 2x.
- −Free cash flow is negative.
- −Going-concern uncertainty due to continued operating losses.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
3 historical score records availablePrevious Score
26
Oct 1, 2026
Change
Unchanged
Current Score
26
Oct 12, 2026
Category Changes
ONMD score was unchanged.
Projected Score
Projected Score
19
Projected Change
-6.4 points
Preliminary comparable-period financial changes suggest decline of approximately 6.4 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$4.46
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Large reported revenue change: +111.4%
Revenue changed sharply from 2024 to 2025. This can reflect a real business change, acquisition, divestiture, discontinued operations, restatement, or reporting-basis change. Compare the underlying filing before treating it as normal growth or decline.
TTM may combine quarters from before and after the event, so its trend can also be distorted.
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $1.5M | $1.4M | $643K | $1.0M | ···· | ···· | ···· |
| Cost of Revenue | $2.4M | $1.9M | $924K | $1.1M | ···· | ···· | ···· |
| Gross Profit | -$983K | -$503K | -$281K | -$129K | ···· | ···· | ···· |
| Research & Development | $1.4M | $1.5M | $1.5M | $2.1M | ···· | ···· | ···· |
| SG&A Expenses | $7.8M | $7.6M | $7.9M | $4.7M | ···· | ···· | ···· |
| Operating Expenses | $9.2M | $9.2M | $9.3M | $6.7M | ···· | ···· | ···· |
| EBITDA | -$8.5M | -$2.7M | -$9.9M | -$33.7M | ···· | ···· | ···· |
| Operating Income | -$10.2M | -$9.7M | -$9.6M | -$6.9M | ···· | ···· | ···· |
| Interest Expense | $33K | $67K | $147K | $11K | ···· | ···· | ···· |
| Income Before Tax | -$8.5M | -$2.8M | -$10.1M | -$33.8M | ···· | ···· | ···· |
| Income Tax Expense | $1K | $1K | $2K | $18K | ···· | ···· | ···· |
| Net Income | -$8.5M | -$2.8M | -$10.1M | -$33.8M | ···· | ···· | ···· |
| Basic EPS | $-1.66 | $-0.60 | $-3.60 | $-47.70 | ···· | ···· | ···· |
| Basic Shares | 5.80M | 4.45M | 2.81M | 708K | ···· | ···· | ···· |
| Diluted Shares | 5.80M | 4.45M | 2.81M | 708K | ···· | ···· | ···· |
Earnings Summary
Revenue
$292000
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.37
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+75.3%
Cash Change
+193.4%
Margin Change
-2667.7 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
What Weakened
- Margins contracted
- Debt increased
Potential Score Impact
Positive indicators included revenue growth, cash levels. Pressure indicators included EPS growth, debt levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 88.4%. EPS declined 147.7%. Cash increased 193.4%. Total debt increased 75.2%. Net income margin declined by 2667.7 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - Healthcare Information ServicesNews
OneMedNet Signs Global Pharmaceutical Intelligence Provider as Channel Partner, Extending Reach in Pharma Market
OneMedNet Adds Leading Hospital System Provider Network, Expanding By Up to 12 Hospitals
OneMedNet Signs Mediplexus as its 11th Channel Partner, Expanding the Company's Real World Data Footprint into Korea and the Asia Pacific Region
OneMedNet Signs Seven Figure Multiyear Agreement to Power a Partner Sold Derivative Data Solution
Rumor Mill · ONMD
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial